ATE388223T1 - Verfahren zur differenzierung einer mesenchym- stammzelle zu einer nervenzelle sowie die nervenzelle enthaltende pharmazeutische zusammensetzung gegen eine neurodegenerative krankheit - Google Patents

Verfahren zur differenzierung einer mesenchym- stammzelle zu einer nervenzelle sowie die nervenzelle enthaltende pharmazeutische zusammensetzung gegen eine neurodegenerative krankheit

Info

Publication number
ATE388223T1
ATE388223T1 AT03754305T AT03754305T ATE388223T1 AT E388223 T1 ATE388223 T1 AT E388223T1 AT 03754305 T AT03754305 T AT 03754305T AT 03754305 T AT03754305 T AT 03754305T AT E388223 T1 ATE388223 T1 AT E388223T1
Authority
AT
Austria
Prior art keywords
cell
nerve cell
stem cell
differentiation
pharmaceutical composition
Prior art date
Application number
AT03754305T
Other languages
English (en)
Inventor
Hyun-Soo Kim
Young-Mo Kang
Kyung-Bock Lee
Sang-Kyo Park
Sang-Kap Lee
Original Assignee
Fcb Pharmicell Co Ltd
Kim Hyun Soo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fcb Pharmicell Co Ltd, Kim Hyun Soo filed Critical Fcb Pharmicell Co Ltd
Application granted granted Critical
Publication of ATE388223T1 publication Critical patent/ATE388223T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
AT03754305T 2003-10-29 2003-10-29 Verfahren zur differenzierung einer mesenchym- stammzelle zu einer nervenzelle sowie die nervenzelle enthaltende pharmazeutische zusammensetzung gegen eine neurodegenerative krankheit ATE388223T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2003/002302 WO2005040362A1 (en) 2003-10-29 2003-10-29 Method for differentiating mesenchymal stem cell into neural cell and pharmaceutical composition containing the neural cell for neurodegenerative disease

Publications (1)

Publication Number Publication Date
ATE388223T1 true ATE388223T1 (de) 2008-03-15

Family

ID=34510740

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03754305T ATE388223T1 (de) 2003-10-29 2003-10-29 Verfahren zur differenzierung einer mesenchym- stammzelle zu einer nervenzelle sowie die nervenzelle enthaltende pharmazeutische zusammensetzung gegen eine neurodegenerative krankheit

Country Status (10)

Country Link
US (1) US7635591B2 (de)
EP (1) EP1687413B8 (de)
JP (1) JP4126060B2 (de)
CN (1) CN100554409C (de)
AT (1) ATE388223T1 (de)
AU (1) AU2003273118B2 (de)
CA (1) CA2543118C (de)
DE (1) DE60319599T8 (de)
HK (1) HK1093755A1 (de)
WO (1) WO2005040362A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069172A2 (en) 2003-01-30 2004-08-19 The Government of the United States of America as represented by the Department of Veterans Affairs Multilineage-inducible cells and uses thereof
JP2006524092A (ja) * 2003-04-24 2006-10-26 コーニンクレッカ　フィリップス　エレクトロニクス　エヌ　ヴィ 非侵襲性左心室容積決定
US20090136461A1 (en) * 2007-11-28 2009-05-28 Moon Suk Kim Neuronal differentiation method of adult stem cells using small molecules
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
NZ591292A (en) 2008-08-20 2012-10-26 Anthrogenesis Corp Improved cell composition and methods of making the same
US8790638B2 (en) * 2009-02-04 2014-07-29 Stemedica Cell Technologies, Inc. Compositions of stem cells and stem cell factors and methods for their use and manufacture
CN102439136A (zh) 2009-03-26 2012-05-02 加州大学校董 产生用于疾病修饰的抑制性rna的间充质干细胞
CN101948803B (zh) * 2010-09-13 2012-09-05 中山大学中山眼科中心 人表皮源性间充质干细胞样多能细胞及其制备方法
WO2012156968A2 (en) * 2011-05-19 2012-11-22 Ariel - University Research And Development Company, Ltd. Use of mesenchymal stem cells for the improvement of affective and cognitive function
KR101446711B1 (ko) * 2011-05-23 2014-10-06 아주대학교산학협력단 간세포 성장인자 유전자 및 염기성 나선-고리-나선 계열의 신경형성 전사인자 유전자가 도입된 성체 줄기세포주 및 그의 용도
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
CN103275070A (zh) * 2013-05-10 2013-09-04 郑彪 调节单核细胞增殖的四环化合物及其应用
CN103919806A (zh) * 2014-04-09 2014-07-16 大连医科大学 骨髓间充质干细胞作为治疗正己烷致周围性神经病的药物的应用
CN104004713A (zh) * 2014-05-14 2014-08-27 安沂华 脐带间充质干细胞诱导培养为神经细胞的方法
WO2022046771A1 (en) * 2020-08-24 2022-03-03 The Johns Hopkins University Juvenile protective factors to arrest and reverse aging in the enteric nervous system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214334B1 (en) * 1991-10-21 2001-04-10 Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogenous neuronal cell transplants to treat neurodegenerative disorders and brain and spinal cord injuries
AU716811B2 (en) * 1994-11-14 2000-03-09 Neurospheres Holdings Ltd Regulation of neural stem cell proliferation
US5736396A (en) * 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US7015037B1 (en) * 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
KR100449141B1 (ko) 2001-04-19 2004-09-21 (주)라이프코드 간엽 간세포를 신경세포로 분화시키는 방법
CA2507395A1 (en) * 2002-12-02 2004-06-17 Anges Mg, Inc. Method for culturing neural stem cells using hepatocyte growth factor

Also Published As

Publication number Publication date
CA2543118C (en) 2009-10-06
EP1687413A1 (de) 2006-08-09
CA2543118A1 (en) 2005-05-06
JP4126060B2 (ja) 2008-07-30
US20070054399A1 (en) 2007-03-08
AU2003273118B2 (en) 2007-05-17
CN1860224A (zh) 2006-11-08
AU2003273118A1 (en) 2005-05-11
HK1093755A1 (en) 2007-03-09
EP1687413B8 (de) 2008-10-01
JP2007528196A (ja) 2007-10-11
DE60319599T8 (de) 2008-10-16
WO2005040362A1 (en) 2005-05-06
EP1687413B1 (de) 2008-03-05
CN100554409C (zh) 2009-10-28
DE60319599T2 (de) 2008-06-26
DE60319599D1 (de) 2008-04-17
US7635591B2 (en) 2009-12-22
EP1687413A4 (de) 2006-11-08

Similar Documents

Publication Publication Date Title
ATE388223T1 (de) Verfahren zur differenzierung einer mesenchym- stammzelle zu einer nervenzelle sowie die nervenzelle enthaltende pharmazeutische zusammensetzung gegen eine neurodegenerative krankheit
WO2016162747A3 (en) Methods and compositions for producing stem cell derived dopaminergic cells for use in treatment of neurodegenerative diseases
EA200601187A1 (ru) Стволовые клетки
DK1155116T3 (da) Anvendelse af kollagenase i fremstillingen af kulturer af neurale stamceller
DE602006018768D1 (de) Konditionell immortalisierte adulte langzeit-stammzellen und verfahren zur herstellung und verwendung von solchen zellen
WO2001036589A3 (en) Human ex vivo immune system
CY1120115T1 (el) Προερχομενα απο μυελο των οστων μεσεγχυματικα αρχεγονα κυτταρα ως μια πηγη νευρικων προγονων
EP2336293A3 (de) Zellkulturverfahren und Vorrichtungen mit Nutzung gasdurchlässiger Materialien
ATE395924T1 (de) Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen
NZ569543A (en) Means and methods for influencing the stability of antibody producing cells
DK1759536T3 (da) In vitro-teknikker til anvendelse med stamceller
DK2274419T3 (da) Fremgangsmåder til fremstilling af hårmikrofollikler og de novopapiller og anvendelse heraf til in vitro-test og in vivo-implantationer
NO971245D0 (no) In vitro-modeller for sentralnervesystemfunksjon og -dysfunksjon
ATE467418T1 (de) Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung
ATE364408T1 (de) Verfahren zur kultivierung von knorpelersatz und biomatrix nach diesem verfahren hergestellt
ES2196172T3 (es) Transplante neuronal utilizando celulas neuroepiteliales pluripotentes.
Chan et al. Heterogeneity of Mesp1+ mesoderm revealed by single-cell RNA-seq
EP1721967A4 (de) Verfahren zur differenzierung mesenchymaler stammzellen zu steroidproduzierenden zellen
GEP20074075B (en) Indazolamides with analgesic activity
ATE501252T1 (de) Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
FR2948381B1 (fr) Procede d'obtention de myofibroblastes.
WO2004113515A3 (en) Tissue modeling in embryonic stem (es) cell system
ATE430314T1 (de) Verfahren und mittel zur beeinflussung von interzellulärer kommunikation und interzellulärem organellentransport
Kim et al. Single‐cell analysis demonstrates how nutrient deprivation creates apoptotic and quiescent cell populations in tumor cylindroids
Grenier et al. Optimization of the Self-Assembly Method for the Production of Psoriatic Skin Substitutes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1687413

Country of ref document: EP